Novo Nordisk Up Nearly 10%, on Pace for Largest Percent Increase Since August 2023 -- Data Talk

Dow Jones12-23 23:03

Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $52.73, up $4.63 or 9.63%

 

--Would be highest close since Oct. 27, 2025, when it closed at $52.89

--On pace for largest percent increase since Aug. 8, 2023, when it rose 17.23%

--Currently up three consecutive days; up 10.75% over this period

--Best three-day stretch since the three days ending Sept. 18, 2025, when it rose 11.2%

--Up 6.85% month-to-date; on pace for best month since Aug. 2025, when it rose 19.95%

--Down 38.7% year-to-date; on pace for worst year since 1984, when it fell 57.59%

--Down 64.11% from its all-time closing high of $146.91 on June 25, 2024

--Down 39.65% from 52 weeks ago (Dec. 24, 2024), when it closed at $87.37

--Down 42.02% from its 52-week closing high of $90.95 on Feb. 25, 2025

--Up 17.26% from its 52-week closing low of $44.97 on Nov. 24, 2025

--Traded as high as $53.20; highest intraday level since Oct. 27, 2025, when it hit $53.22

--Up 10.6% at today's intraday high; largest intraday percent increase since Jan. 24, 2025, when it rose as much as 10.94%

 

All data as of 9:55:09 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

December 23, 2025 10:03 ET (15:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment